CALGARY, Alberta, April 19, 2018 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM), a clinical-stage, autologous cell-therapy company, is pleased to announce that the United States Food and Drug Administration (“FDA”) has raised no objections to the Company’s Investigational New Drug (“IND”) application. This allows the Company to expand its Phase II clinical trial for critical limb ischemia (“CLI”) to enroll patients at clinical sites across the United States in addition to Canada, where the Company has already received Health Canada approval. This is a key milestone in the Company’s international Phase II double-blind, randomized, placebo-controlled clinical trial. [Read more…]
How iPSCs are Becoming an Emerging Area of Stem Cell Research
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and diverse market for iPSC research tools has emerged. Included below is a ten-year history of iPSC grants (source: RePORT.NIH.gov), clinical trials (source: ClinicalTrials.gov), and scientific publications (source: PubMed.gov).
Both graphs below reveal the iPSC market is expanding. [Read more…]
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility
-
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases
-
With 300,000 square feet (27,870 square meters), it is the largest dedicated cell-and-gene-therapy manufacturing facility in the world
-
Facility to reach 200 full-time staff by end of 2018 and continue to recruit high-value positions as market demand increases
Cellect Announces a Major Milestone for Enabling Stem Cells Production
Highlights
- Successfully completes POC testing for first ever scalable production of ApoTainer™
- Cellect’s ApoTainer™ built to replace complex laboratory procedures for stem cell extraction at a fraction of the time and cost
- Dr. Shai Yarkoni, Cellect CEO commented: “We believe that the expected demand for stem cells as raw material for regenerative medicine will explode over the next five years. Our ApoTainer™ is intended to ensure this demand is met with a cost-effective quality manufacturing of stem cells.”
- The ApoTainer™ is covered by a portfolio of IP including a patent application for apoptotic selection of stem cells using FasL-coated magnetic beads
Kite Pharma Execs Form Allogene with Pfizer’s CAR-T Assets and $300M
-
Creates alliance with Allogene Therapeutics, a biotechnology company co-founded and led by former executives of Kite Pharma that is positioned to expedite the development of allogeneic CAR T cell therapy
-
Allogene Therapeutics, a Two River portfolio company, was formed with one of the largest Series A financings in biotechnology of $300 million from a premier investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer
-
Pfizer will hold a 25 percent ownership stake in Allogene Therapeutics
- « Previous Page
- 1
- …
- 235
- 236
- 237
- 238
- 239
- …
- 334
- Next Page »